
|Videos|April 22, 2014
Personalizing Analgesic Selection for Breakthrough Pain
Advertisement
Episodes in this series

For High-Definition, Click
The pharmacokinetics are similar between the varying transmucosal immediate-release fentanyl (TIRF) products, making treatment selection difficult in terms of efficacy. As a result, the optimal therapy to administer should be tailored based on patient characteristics, notes Marc Rappaport, DO.
If a patient has mucositis, sublingual TIRF products are better tolerated than fentanyl nasal sprays, which adhere directly to the mucosa. Rappaport recommends developing familiarity with several of the available TIRF products, in order to be able to personalize the treatment decision.
Advertisement
Related to this article

Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.

Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.

The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
Five Under 5: Top Oncology Videos for the Week of 7/12
3
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5











